Report post
Pfizer CEO Bourla predicts no major M&A activity in 2024, yet Pfizer acquires cancer-drug Maker Seagen for $43 billion. Bourla cites Seagen's advanced cancer-fighting technology as a key factor in the acquisition. The deal underscores Pfizer's commitment to innovation in healthcare. Expectations for Pfizer's sales, M&A, mRNA, and weight loss drug strategies remain strong.

The World's Leading Crypto Trading Platform

Get my welcome gifts